Predicting Success and Failure on Long-acting Cabotegravir/Rilpivirine

Daniel R. Kuritzkes, MD
Professor, Harvard Medical School
Chief, Division of Infectious Diseases
Brigham and Women's Hospital, Boston, MA

Videos of live meetings of PRN in NYC are owned and published by Physicians’ Research Network, Inc. Copyright © 2022. All rights reserved.



CME VIDEOTop of page

How to Obtain CME Credit:Top of page

Click here to take the CME Evaluation and Post-Meeting Survey

About the Presenters:Top of page

Daniel R. Kuritzkes, MD received his BS and MS degrees in Molecular Biophysics and Biochemistry from Yale University, and his MD from Harvard Medical School. He completed his clinical and research training in internal medicine and infectious diseases at Massachusetts General Hospital and was a visiting scientist at the Whitehead Institute for Biomedical Research before joining the faculty at the University of Colorado Health Sciences Center. Dr. Kuritzkes returned to Harvard Medical School in 2002, where he is now the Harriet Ryan Albee Professor of Medicine and Chief, Division of Infectious Diseases at Brigham and Women’s Hospital. Dr. Kuritzkes has published extensively on antiretroviral therapy and drug resistance in HIV-1 infection. He has chaired several multicenter studies of HIV therapy and previously chaired the AIDS Clinical Trials Group. He has served on numerous NIH committees, including as a member of the NIH Office of AIDS Research Advisory Council. He is a former member of the Department of Health and Human Services panel on guidelines for antiretroviral therapy and a past Chair of the HIV Medicine Association Board of Directors. He has been a member of several editorial boards, and serves as an Associate Editor of the Journal of Infectious Diseases. His research interests focus on HIV therapeutics, antiretroviral drug resistance, HIV eradication and more recently, COVID-19.

Learning Objectives: Top of page

At the completion of this educational session, learners will:
1. Be aware of the outcomes of treatment with CAB/RPV LA.
2. Understand the risks for failure of CAB/RPV LA.
3. Appreciate the virological basis for increased risk of CAB resistance in HIV subtype A6.

CME Information:Top of page


This CME activity has approved for AMA PRA Category 1 Credit™ for September 14, 2022, as a live activity.  This activity will also be available as an enduring activity from September 15, 2022, through September 13, 2025.

The target audience is all physicians, NPs and PAs involved or interested in HIV education.

This online video and post-activity evaluation are one hour in length.

Accreditation Statement:Top of page


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of the State of New York (MSSNY) and the Physicians’ Research Network (PRN). MSSNY is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Society of the State of New York designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement:Top of page

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Disclosure Statement:Top of page

Policies and standards of the Medical Society of the State of New York and the Accreditation Council for Continuing Medical Education require that speakers and planners for continuing medical education activities disclose any relevant financial relationships they may have with commercial interests whose products, devices, or services may be discussed in the content of a CME activity.

- Dr. James F. Braun (Course Director) has no relevant financial relationships to disclose.

- Dr. William M. Valenti (Moderator) has no relevant financial relationships to disclose.

- Dr. Daniel R. Kuritzkes (Presenter) has had the following personal financial relationships in the past 24 months with manufacturers of the products or services that may be presented in this CME activity: Consultant to: AbbVie, Gilead, GlaxoSmithKline, Janssen, Merck, and ViiV; Research Support from: Gilead, Merck, and ViiV. Dr. Kuritzkes will submit their slides in advance for adequate peer review and will support their presentation and clinical recommendations with the best available evidence from the medical literature. All relevant financial relationships have been mitigated.

Financial Support:Top of page

This PRN CME activity is funded in part by unrestricted educational grants from:
Gilead Sciences; Janssen Therapeutics, a division of Janssen Products, LP; Merck & Co.; and ViiV Healthcare

You must be logged in to post a comment. Login | Register